Giuseppe Curigliano: With T-DXd for HR-Positive Metastatic Breast Cancer
Giuseppe Curigliano shared an article on X:
“DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive Metastatic Breast Cancer. How Do These Results Impact Practice for All Patients?”
Authors: Giuseppe Curigliano and Aditya Bardia.
Source: Giuseppe Curigliano/X
Giuseppe Curigliano, MD, PhD, is the Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology. He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues. He is the Editor-in-Chief of ESMO Open, the European Society for Medical Oncology’s open-access journal.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023